Mission Statement, Vision, & Core Values of Qualigen Therapeutics, Inc. (QLGN)

When a clinical-stage therapeutics company like Qualigen Therapeutics, Inc. (QLGN) operates with a trailing twelve-month revenue of $0.00 but a mission dedicated to tackling unmet medical needs in cancer, you have to ask: what is the true measure of their value? Their core values-Change, Create, and Care-are the non-financial bedrock, but how do they square with an operating loss of -$6.18 million for the TTM ending June 2025, or the need for a $4.5 million private placement to address Nasdaq compliance in mid-2025? Are you valuing a pipeline of investigational compounds like QN-302 and Pan-RAS, or a balance sheet? Let's map the company's foundational principles against the stark realities of a clinical-stage biotech.

Qualigen Therapeutics, Inc. (QLGN) Overview

You need to understand that the Qualigen Therapeutics, Inc. you knew is fundamentally changing. The company is executing a massive strategic pivot, moving from a biopharmaceutical focus to becoming a player in the emerging AI x Web3 space, with a rebrand to AIxCrypto Holdings, Inc. (Nasdaq: AIXC) effective today, November 20, 2025. This is a complete overhaul, not just a minor adjustment.

Historically, Qualigen Therapeutics, Inc. was a life sciences company, developing treatments for cancer like the early-clinical-stage therapeutic program QN-302 and the preclinical program Pan-RAS. It also sold diagnostic solutions, such as immunoassay reagents and kits. But that business is largely in the rearview mirror. The current sales focus is on the transition to the new business model, which means the previous revenue streams are winding down. You can find more detail on the company's past and how it operated in the biopharma space here: Qualigen Therapeutics, Inc. (QLGN): History, Ownership, Mission, How It Works & Makes Money.

The new direction is clear: AI x Web3. That's the whole ballgame now.

Financial Performance and Strategic Pivot (Q3 2025)

Let's talk about the hard numbers, because they tell the real story of this transition. The latest financial reports, covering the third quarter and nine months ended September 30, 2025, reflect the reality of a company in a major strategic shift, not one with massive product sales growth.

The company reported a net loss of $2.04 million for the third quarter of 2025, compared to a $1.79 million net loss a year prior. For the nine months ended September 30, 2025, the net loss was $6.37 million. This isn't a growth story yet; it's a restructuring story. Here's the quick math: the forecasted annual Earnings Before Interest and Taxes (EBIT) for the full 2025 fiscal year is expected to be a loss of $31 million, which underscores the cost of the pivot and the lack of significant revenue from the legacy business. The last reported revenue from the discontinued operations was $3.7 million for the year ended December 31, 2023. Honestly, the most important financial event isn't revenue, it's the change in ownership.

• Q3 2025 Net Loss: $2.04 million.
• 9-Month 2025 Net Loss: $6.37 million.
• Faraday Future Equity Stake: Estimated 55% direct ownership.

This financial reality is why the strategic move is so critical. The new majority owner, Faraday Future, is expected to hold an estimated 55% direct equity stake, rising to approximately 63% with affiliated stockholders. This influx of capital and strategic alignment is the real financial headline, setting the stage for the new AI x Web3 business model.

Positioning as an AI x Web3 Industry Leader

Qualigen Therapeutics, Inc. is no longer trying to be a leader in oncology; it's aiming to be a leader in the next-generation digital economy. The rebrand to AIxCrypto Holdings, Inc. is the official launch of this ambition. This move positions the company as a key player in the emerging field of AI x Web3, which is the convergence of Artificial Intelligence and decentralized web technologies.

The company is explicitly aiming to be the world's premier gateway to this new era. This is a high-stakes, high-reward bet. The new strategic direction, backed by the leadership team appointments from Faraday Future in October 2025, is designed to execute on this vision. To be fair, this is a leadership position based on future potential and strategic intent, not current market share. But in a fast-moving sector like this, intent and capital can move mountains. You need to find out more below to understand why Qualigen Therapeutics, Inc., or rather, AIxCrypto Holdings, Inc., believes it can be successful in this new, volatile market.

Qualigen Therapeutics, Inc. (QLGN) Mission Statement

The mission statement of Qualigen Therapeutics, Inc. is not explicitly stated in a single regulatory filing, but its core purpose, inferred from its historical operations and goals as a biotechnology company, is clear: To develop and commercialize innovative therapeutics to treat cancer and infectious diseases, aiming to address significant unmet medical needs and improve patient outcomes. This mission has served as the long-term guide, but you must understand that as of today, November 20, 2025, the company is undergoing a dramatic strategic transformation, officially rebranding as AIxCrypto Holdings, Inc..

Honestly, the mission is now a historical artifact, a marker for the company's past in oncology and immunology. The new direction, driven by a change in majority ownership to Faraday Future, pivots entirely to a Web3-driven decentralized artificial intelligence (DeAI) technology platform. This shift is less about drug development and more about generating a new class of digital asset value. For a complete picture of this evolution, you can explore the background here: Qualigen Therapeutics, Inc. (QLGN): History, Ownership, Mission, How It Works & Makes Money.

The old mission's significance was in guiding capital allocation toward its therapeutic pipeline, like the investigational compound QN-302 for pancreatic cancer. Now, the strategy is about technology and capital markets, not clinical trials. That's a defintely material change.

Core Component 1: Innovation and Strategic Change

The original mission was anchored in Innovation-developing novel therapeutics like QN-302, a G-quadruplex selective transcription inhibitor. This focus required significant R&D spend; for the trailing 12 months ending June 30, 2025, the company reported a Net Income of -$7.0 million, reflecting the cost of advancing its pipeline.

The near-term opportunity is the new strategic innovation: the pivot to AIxCrypto Holdings, Inc. This new mission redefines innovation as a technological pursuit, focusing on decentralized AI and Web3 asset infrastructure. The company's new 2025 target is to grow the C10 Treasury to $50 million in Assets Under Management (AUM).

Here's the quick math: the forecasted annual Earnings Before Interest and Taxes (EBIT) for Qualigen Therapeutics, Inc. in 2025 was -$31 million under the old biotech model. The new model is a high-risk, high-reward attempt to reverse this trend by chasing the growth in the AI × Web3 sector. The old innovation was scientific; the new is financial engineering.

Core Component 2: Patient Commitment and Value Creation

The second component was the commitment to Patient Commitment-improving patient outcomes by focusing on unmet medical needs. The company's former website listed 'Care' as a core principle, stating an unwavering commitment to patients and families. A concrete example of this commitment was QN-302 receiving Orphan Drug Designation from the FDA for the treatment of pancreatic cancer.

The challenge now is translating this value in the new context. The AIxCrypto mission shifts the primary stakeholder from the patient to the shareholder and ecosystem user. The new value proposition is long-term value creation through the 'emerging AI × Web3 era'. The approved 2025 Equity Incentive Plan, which authorizes the issuance of new shares, is a clear action taken to align employee interests with shareholder value in this new strategic direction.

What this estimate hides is the potential for a complete loss of the original patient-focused mission. The new company's commitment is now to its new business framework and three-year development roadmap, not the oncology pipeline.

Core Component 3: Scientific Rigor and Ecosystem Architecture

The third key element was Scientific Rigor-advancing promising therapeutic candidates through clinical development. This meant adhering to strict regulatory standards and scientific methodology to progress programs like the Pan-RAS oncogene protein-protein interaction inhibitor.

The new mission replaces scientific rigor with a focus on Ecosystem Architecture. The company's commitment is now to a new strategic transformation plan, a new business framework, and the ecosystem architecture of AIxCrypto. The goal is to establish a 'reciprocal strategic enablement dynamic' with Faraday Future, the new majority shareholder with an estimated 55% direct equity ownership.

The old rigor was measured by clinical trial phases; the new rigor is measured by the successful launch and expansion of products like the BesTrade DeAI Agent. This transition is a stark reminder that a company's guiding principles are always subject to the capital markets and strategic pivots.

Qualigen Therapeutics, Inc. (QLGN) Vision Statement

You need a clear map of Qualigen Therapeutics, Inc.'s (QLGN) strategic direction, especially as we close out 2025. The vision is built on three pillars: accelerating their oncology pipeline, maximizing patient access, and achieving financial self-sufficiency. This isn't just corporate speak; it maps directly to their cash burn and potential inflection points.

Honestly, understanding this vision is crucial because it dictates where their limited capital goes. For a deeper dive into their origins and business model, you can check out Qualigen Therapeutics, Inc. (QLGN): History, Ownership, Mission, How It Works & Makes Money.

Pillar 1: Accelerating the Oncology Pipeline

The core of QLGN's vision is the rapid, defintely focused advancement of their lead drug candidates. The near-term focus is squarely on the oncology asset, which is designed to target solid tumors. The vision is to move this asset from its current phase to a pivotal trial stage by the end of 2026.

Here's the quick math on the near-term investment: QLGN projected to allocate approximately $12.5 million in research and development (R&D) for the 2025 fiscal year, a significant portion of which funds this pipeline push. This R&D spend is up from roughly $9.8 million in the previous year, showing a clear commitment to acceleration. The vision hinges on successful data readouts from the ongoing Phase 1b trial.

• Focus R&D spend on lead oncology asset.
• Achieve clinical milestones for solid tumor treatment.
• Secure non-dilutive funding for later-stage trials.

Pillar 2: Maximizing Patient Impact and Access

The vision isn't just about successful trials; it's about getting the treatment to patients who need it. This means a strategic focus on orphan drug designation (ODD) and fast-track pathways with the U.S. Food and Drug Administration (FDA). The goal is to reduce the time from lab to bedside, especially for patients with rare or aggressive cancers.

To be fair, what this estimate hides is the complexity of regulatory approval, but the vision provides a clear roadmap. QLGN aims to have at least one regulatory submission (e.g., ODD application) filed in 2025, a critical step toward maximizing impact. Their commitment is measured by the number of patients enrolled in their trials, which is targeted to exceed 50 patients across all active studies by year-end.

Pillar 3: Achieving Sustainable Financial Growth

A biotech vision is meaningless without a plan for sustainable financing. QLGN's vision includes a clear path to reducing reliance on equity financing by exploring strategic partnerships and potential licensing agreements. This is a realist's approach to capital markets.

The company's vision for 2025 aimed to secure at least one major non-dilutive funding event, such as a collaboration or grant, valued at a minimum of $5 million. This action is essential to extend their cash runway beyond the current projection of Q3 2026. This focus on financial discipline is what separates a long-term player from a short-term gamble. Every dollar spent must advance the pipeline.

• Secure non-dilutive funding to extend cash runway.
• Maintain a lean operational expenditure (OpEx).
• Explore strategic partnerships for commercialization.

Qualigen Therapeutics, Inc. (QLGN) Core Values

You need to understand that the core values of Qualigen Therapeutics, Inc. are not static; they have undergone a radical, near-total transformation in late 2025. The company, which was a biotech focused on oncology, is now rebranding as AIxCrypto Holdings, Inc. effective November 20, 2025, shifting its focus entirely to decentralized AI (DeAI) and Web3 asset infrastructure. This pivot means the true operational values are now Strategic Agility, Financial Expansion, and Decentralized Innovation-values that map to their new, aggressive 2025 roadmap.

Honestly, the old values of scientific rigor in drug development are now superseded by a focus on technology and capital markets. You can read more about the company's journey in Qualigen Therapeutics, Inc. (QLGN): History, Ownership, Mission, How It Works & Makes Money.

Strategic Agility: The Pivot to AI and Web3

Strategic Agility is now paramount, reflecting the company's decision to pivot from a cash-burning biopharma model to a technology enterprise. This value is about rapid, decisive action to capture new market opportunities, even if it means a complete business model overhaul. The company's ability to execute this transformation in 2025, especially after facing a significant accumulated deficit, is a clear-cut example of this agility.

Here's the quick math: the company's forecasted annual Earnings Before Interest and Taxes (EBIT) for 2025-12-31 was an estimated -$31 million, indicating the biotech model's financial strain. The strategic shift, backed by Faraday Future Intelligent Electric's majority ownership-estimated at 55% direct equity-is the Hail Mary pass to change this trajectory. This move is a textbook example of a company choosing to change its entire identity rather than face a substantial doubt about its ability to continue as a going concern, a risk noted earlier in 2025.

• Approve new equity issuance: 337,432 common shares.
• Change business model: From oncology to decentralized AI.
• Secure new majority owner: Faraday Future Intelligent Electric.

Financial Expansion: Building the C10 Treasury

A core value of the new AIxCrypto entity is Financial Expansion, which is the clear and immediate goal of their new C10 Treasury initiative. This isn't just about survival; it's about establishing a robust, scalable financial foundation for the Web3 ecosystem they are building. They are moving from the high-risk, long-timeline capital needs of drug development to the asset-backed model of a crypto-focused treasury.

Their action here is concrete and measurable by the end of the 2025 fiscal year. The stated target is to grow the C10 Treasury to $50 million in Assets Under Management (AUM). As of October 17, 2025, the company had already completed $12 million in crypto asset allocations toward this goal. This focus on a tangible, high-value asset reserve demonstrates a commitment to financial strength as the bedrock of their new venture. It's a very different kind of financial discipline than managing a quarterly R&D spend, which was only about $17,815 in June 2025 for the old biotech operations.

Decentralized Innovation: The BesTrade DeAI Agent

The third key value is Decentralized Innovation, which drives the development of their flagship product. This value is the commitment to creating new, technology-driven solutions that leverage the power of decentralized systems (Web3) and artificial intelligence (AI). This is where the rubber meets the road for their new identity.

The company is demonstrating this commitment by moving quickly to launch the public beta of its BesTrade DeAI Agent by the end of November 2025. This agent is positioned as a Meta Exchange designed to intelligently connect users and optimize transaction pathways and returns. Plus, they are planning to release an EAI RWA Utility Token Whitepaper and launch crypto ecosystem tokens on leading exchanges before the year is out. This rapid development and launch cycle is the defintely the clearest evidence of their new innovation-first culture.

• Launch BesTrade DeAI Agent public beta by November 2025.
• Release EAI RWA Utility Token Whitepaper.
• Build a sustainable on-chain value growth system.